A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.

Trial Details

NCT ID
NCT04307576
Phase
PHASE3
Sponsor
Mats Heyman
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Omitted Doxorubicin
  • Omitted Vincristine+Dexamethasone pulses
  • Inotuzumab Ozogamicin+Standard Maintenance Therapy
  • Imatinib
  • 6-tioguanine+Standard Maintenance Therapy
  • Blinatumomab
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Edegem, Belgium|51.15662,4.44504
  • Ghent, Belgium|51.05,3.71667
  • Leuven, Belgium|50.87959,4.70093
  • Liège, Belgium|50.63373,5.56749

Key Eligibility Criteria

  • Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tu…
  • Age 0 - \< 46 years (one day before 46th birthday) at the time of diagnosis with the exception of infants with KMT2A-rearranged (KMT2A-r) BCP ALL.
  • Patients with surface immunoglobulin negative (sIG-) BCP-ALL and an IG::MYC rearrangement, unless they have a concurrent BCL2/6 rearrangement. T-AL…
  • Informed consent signed by the patient and/or parents/legal guardians according to country-specific age-related guidelines.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →